IP Library Granted Patent US 7,589,059
Granted Patent B2
US 7,589,059 · App. 10/628,792 · Granted Sep 15, 2009

Delivery of molecules and complexes to mammalian cells in vivo

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,589,059
App. No.
10/628,792
Granted
Sep 15, 2009
Kind
B2
Abstract

Disclosed is a system for providing in vivo delivery of molecules or complexes to extravascular mammalian cells using an intravascular administration route. The molecules or complexes are inserted in an injection solution into a mammalian vasculature. Insertion of the injection solution at an appropriate rate transiently increases the volume of extravascular fluid in the tissue thereby facilitating delivery of the molecule to the cell.

Claims (25)

1. A process for delivering a protein or peptide to an extravascular cell in a mammalian target tissue in vivo comprising: inserting an injection solution containing the protein or peptide into the lumen of an efferent or afferent vessel of the target tissue wherein the inserting of the injection solution results in an increase in pressure in a vein of the target tissue of 10 mm Hg or greater thereby resulting in delivery of the protein or peptide to the extravascular cell.

2. The process of claim 1 wherein fluid flow out of the target tissue is occluded.

3. The process of claim 1 wherein the protein or peptide consists of a biologically active protein or peptide.

4. The process of claim 3 wherein the protein or peptide is greater than 5 kDa.

5. The process of claim 4 wherein the protein or peptide is greater than 30 kDa.

6. The process of claim 5 wherein the protein or peptide is greater than 500 kDa.

7. The process of claim 1 wherein the protein or peptide consists of a therapeutic molecule.

8. The process of claim 1 wherein the protein or peptide is in a complex.

9. The process of claim 1 wherein the injection solution contains a compound that increases vessel permeability.

10. The process of claim 9 wherein the compound consists of a vasodilator.

11. The process of claim 1 wherein the cell consists of a liver cell.

12. The process of claim 11 wherein the liver cell consists of a hepatocyte.

13. The process of claim 1 wherein the cell consists of a skeletal muscle cell.

14. The process of claim 1 wherein the cell consists of a heart muscle cell.

15. The process of claim 1 wherein the cell consists of a prostate cell.

16. The process of claim 1 wherein the vessel consists of a blood vessel.

17. The process of claim 16 wherein the blood vessel consists of an artery.

18. The process of claim 16 wherein the blood vessel consists of a vein.

19. The process of claim 1 wherein the vessel consists of a bile duct.

20. The process of claim 1 wherein the injection solution contains less than 20 mM salt.

21. The process of claim 20 wherein the injection solution contains less than 5 mM salt.

22. The process of claim 1 wherein the injection solution contains zwitterions.

23. The process of claim 1 wherein the injection solution is hypotonic.

24. The process of claim 1 wherein the injection solution is hypertonic.

25. A process for delivering a protein or peptide to an extravascular in vivo mammalian cell in a target tissue comprising: rapidly inserting a sufficient volume of injection solution containing the protein or peptide into the lumen of an efferent or afferent vessel of the target tissue and impeding fluid flow away from the tissue during the injection wherein the inserting of the injection solution results in an increase in pressure in a vein of the target tissue of 10 mm Hg or greater thereby resulting in delivery of the protein or peptide to the extravascular mammalian cell in the tissue.

Assignments (2)
CHANGE OF NAME Recorded Aug 10, 2009
From: MIRUS BIO CORPORATION
To: ROCHE MADISON INC.
Reel/Frame 023081/0128 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 19, 2008
From: SUBBOTIN, VLADIMIR; HEGGE, JULIA; HERWEIJER, HANS; HAGSTROM, JAMES E; WOLFF, JON A; BUDKER, TATYANA; MONAHAN, SEAN D
To: MIRUS BIO CORPORATION
Reel/Frame 021556/0181 →